Table 1.
Baseline characteristics of participants in each arm.
| Characteristic | Ganitumab (n = 106) | Control (n = 128) |
|---|---|---|
| Median age (range), yr | 48 (23–70) | 47.5 (24–77) |
| Ethnicity, n (%) | ||
| White | 86 (81%) | 101 (79%) |
| African American | 12 (11%) | 18 (14%) |
| Asian | 8 (8%) | 7 (5%) |
| Other/Mixed | 0 (0%) | 2 (2%) |
| HR Status, n (%) | ||
| Positive | 58 (55%) | 66 (52%) |
| Negative | 48 (45%) | 62 (48%) |
| Mammaprint Status, n (%) | ||
| MP.Hi1 | 47 (44%) | 70 (55%) |
| MP.Hi2 | 59 (56%) | 58 (45%) |
| Median Tumor Size by MRI (range), cm | 3.6 (0.8–14.7) | 3.9 (1.2–15) |
| Baseline node status, n (%) | ||
| Palpable | 26 (25%) | 60 (47%) |
| Non-palpable | 67 (63%) | 59 (46%) |
| N/A | 13 (12%) | 9 (7%) |